Liquid chromatography–tandem mass spectrometric assay for sorafenib and sorafenib–glucuronide in mouse plasma and liver homogenate and identification of the glucuronide metabolite
- 15 January 2009
- journal article
- Published by Elsevier BV in Journal of Chromatography B
- Vol. 877 (3), 269-276
- https://doi.org/10.1016/j.jchromb.2008.12.026
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Hepatocellular Carcinoma: The Role of the North American GI Steering Committee Hepatobiliary Task Force and the Advent of Effective Drug TherapyThe Oncologist, 2007
- Development of a rapid and sensitive LC–MS/MS assay for the determination of sorafenib in human plasmaJournal of Pharmaceutical and Biomedical Analysis, 2007
- Sorafenib inhibits the angiogenesis and growth of orthotopic anaplastic thyroid carcinoma xenografts in nude miceMolecular Cancer Therapeutics, 2007
- A rapid and sensitive method for determination of sorafenib in human plasma using a liquid chromatography/tandem mass spectrometry assayJournal of Chromatography B, 2007
- In vitro characterization of the human biotransformation and CYP reaction phenotype of ET-743 (Yondelis®, Trabectidin®), a novel marine anti-cancer drugInvestigational New Drugs, 2006
- Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokineticsCancer Chemotherapy and Pharmacology, 2005
- Validation of a liquid chromatography assay for the quantification of the Raf kinase inhibitor BAY 43-9006 in small volumes of mouse serumJournal of Chromatography B, 2004
- Discovery of a novel Raf kinase inhibitor.Endocrine-Related Cancer, 2001
- BIOANALYTICAL LIQUID CHROMATOGRAPHIC METHOD VALIDATION. A REVIEW OF CURRENT PRACTICES AND PROCEDURESJournal of Liquid Chromatography & Related Technologies, 2000
- Bioanalytical Method Validation—A Revisit with a Decade of ProgressPharmaceutical Research, 2000